Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Inari Medical ( (NARI) ) has provided an update.
Inari Medical has entered into a definitive agreement to be acquired by Stryker Corporation for $80 per share in cash, valuing the transaction at approximately $4.9 billion. This acquisition, which will expand Stryker’s portfolio in the peripheral vascular segment, is expected to close by the end of the first quarter of 2025, subject to regulatory and other customary conditions.
More about Inari Medical
Inari Medical, Inc. is a company that specializes in creating innovative solutions for venous thromboembolism (VTE), a condition affecting up to 900,000 lives annually in the United States. The company offers mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, providing alternatives to thrombolytic drugs.
YTD Price Performance: -3.92%
Average Trading Volume: 939,943
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.91B
For a thorough assessment of NARI stock, go to TipRanks’ Stock Analysis page.
